Journal of Clinical and Experimental Ophthalmology
Open Access
ISSN: 2155-9570
ISSN: 2155-9570
Daniel C Chung
Department of Ophthalmology
University of Pennsylvania, USA
Dr. Chung has received his medical degree from the New York College of Osteopathic Medicine at the New York Institute of Technology in 1994. He then served as an Intramural Research Training Award Fellow at the National Eye Institute of the National Institutes of Health. He further pursued his clinical training in ophthalmology, at the Summa Health Hospitals in Ohio, culminating as a fellow in pediatric ophthalmology and ocular genetics research at the Cole Eye Institute of the Cleveland Clinic Foundation. Currently, he is working as a Senior Research Investigator/Adjunct Assistant Professor of Ophthalmology in the F.M. Kirby Center for Molecular Ophthalmology, at the University of Pennsylvania School of Medicine. He has authored numerous publications on retinal gene therapy and other ciliopathies, and has been an invited lecturer nationally and internationally on topics of gene therapy. He has been invited to share his expertise in vector delivery to pre-clinical models of retinal degeneration, both nationally and internationally. He is a member of the American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, American Society of Gene and Cell Therapy, International Society of Genetic Eye Diseases and Retinoblastoma, and the American Society of Human Genetics
genetic correction of ciliopathies of the retina, kidney and inner ear. He has been involved in the development of vector delivery to pre-clinical animal models for inherited retinal degeneration, polycystic kidney disease and Usher syndrome, at all developmental ages. In addition to his basic gene therapy research interests, he is also involved in the ongoing RPE65 Leber’s Congenital Amaurosis clinical trials at the Children’s Hospital of Philadelphia/University of Pennsylvania. Utilizing both adeno-associated viral and non-viral vectors, Dr. Chung is involved in developing and implementing new gene therapy strategies for retina degeneration, and other ciliopathies.